Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;28(4):e54.
doi: 10.3802/jgo.2017.28.e54.

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference

Ji Yon Agnes Jang  1 , Nozomu Yanaihara  2 , Eric Pujade-Lauraine  3 , Yoshiki Mikami  4 , Katsutoshi Oda  5 , Michael Bookman  6 , Jonathan Ledermann  7 , Muneaki Shimada  8 , Takako Kiyokawa  9 , Byoung Gie Kim  10 , Noriomi Matsumura  11 , Tsunehisa Kaku  12 , Takafumi Kuroda  1 , Yoko Nagayoshi  1 , Ayako Kawabata  1 , Yasushi Iida  1 , Jae Weon Kim  13 , Michael Quinn  14 , Aikou Okamoto  1
Affiliations
Review

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference

Ji Yon Agnes Jang et al. J Gynecol Oncol. 2017 Jul.

Abstract

There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).

Keywords: Ovarian Neoplasms; Rare Diseases.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504. - PubMed
    1. Boyd C, McCluggage WG. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol. 2012;36:368–375. - PubMed
    1. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114:48–52. - PubMed
    1. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–368. - PubMed
    1. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108:510–514. - PubMed

MeSH terms

Substances